Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san diego blog main
san diego top stories
9
×
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
biotech
clinical trials
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
medicare
pfizer
alnylam pharmaceuticals
amgen
cancer
deals
gene therapy
merck
novartis
spark therapeutics
venture capital
What
patients
9
×
drug
fda
bio
roundup
therapy
ago
alnylam
developers
disease
gene
healthcare
market
medicine
moves
pfizer
sets
time
acquisitions
add
advantages
akcea
albert
amyloidosis
approve
approved
aren’t
attr
available
awaits
bar
battle
becker
biggest
billions
biological
bourla
brings
called
cancer
Language
unset
unknown
Current search:
patients
×
" san diego top stories "
×
@xconomy.com
4 years ago
Neurocrine Gets FDA Nod for Once-Daily “Add-On” Parkinson’s Pill
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets